Thermo Fisher Signed Reseller Agreement for Evosep Eno
The partnership integrates Evosep's high-throughput separation platform into Thermo Fisher's mass spectrometry portfolio.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do corporate partnerships between major laboratory suppliers improve access to advanced scientific technology?
Thermo Fisher Scientific and Evosep have entered into a global reseller agreement to distribute the Evosep Eno separation platform. The platform is designed for proteomics workflows and is classified as general laboratory equipment.
Why it matters
This agreement bridges Evosep's specialized separation technology with the extensive global commercial reach of Thermo Fisher Scientific. It aims to accelerate the broader adoption of standardized, high-throughput proteomics pipelines across research laboratories.
The Evosep Eno functions as a hardware platform for proteomics, which is the large-scale study of proteins. It integrates directly with existing Thermo Fisher mass spectrometry instruments, a technique used to measure the mass-to-charge ratio of ions for identifying biological molecules.
The players
Thermo Fisher Scientific
A global supplier of scientific instrumentation, reagents, and software for the biotechnology and life sciences industries.
Evosep
A developer of specialized liquid chromatography hardware designed to standardize and accelerate proteomics workflows.
The details
The Evosep Eno system provides a standardized, high-throughput method for proteomics, focusing on the separation of complex biological samples. By integrating this platform with Thermo Fisher Scientific's mass spectrometry portfolio, the companies aim to streamline the workflow from sample preparation to analytical detection. This hardware serves as a foundational component for labs conducting deep-scale protein analysis.
Timeline
September 28, 2026: Evosep announced the reseller agreement at the HUPO 2026 conference in Singapore.
The Tech Race
The partnership aligns with the standardized analytical benchmarks established by the Human Proteome Organization (HUPO) annual world congress. This move consolidates the proteomics hardware market by linking two major infrastructure providers to set a higher baseline for analytical throughput.
Research laboratories can now acquire the Evosep Eno platform through their existing Thermo Fisher Scientific procurement channels. The agreement is effective immediately and shifts the logistics of obtaining high-throughput proteomics hardware for clinical and research users.
The takeaway
The move signals a trend toward integrated, turnkey proteomics solutions in professional laboratory settings. Watch for potential updates regarding system compatibility at the next HUPO industry gathering.
Further reading
For more on the current landscape of analytical instrumentation, visit our Biotech section.
Live Poll
Do corporate partnerships between major laboratory suppliers improve access to advanced scientific technology?
